AlzGene

AlzGene - Gene overview of all published AD-association studies for LDLR

Gene:

LDLR (FH; FHC)

View on ALSGene

Protein:

low density lipoprotein receptor

Chromosome:

19 (View: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y MT)

Status:

Updated 18 April 2011

1. Case-Control Studies (by ethnic group)
				AD Cases				Normal Controls
Study	Population	Source	# Polys	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result	Comment
Caucasian
Cheng, 2005	USA	CL	2 (detail)	180 (71%)	C	70.8 + 8.1 (50-92)	-	141 (59%)	72.3 + 8.4 (51-89)	Positive
Corder, 2006	Overlaps with Cheng, 2005	CL	2 (detail)	-	-	-	-	-	-	n.a.
Giedraitis, 2009	Sweden (ULSAM)	CL	4 (detail)	86 (0%)	C	80.2 (72-85)	-	404 (0%)	81.8 (80-84)	Negative
Gopalraj, 2004	USA (UKY)	CL,CO	3 (detail)	118 (73%)	C	74.3 + 6.1 (-)	-	133 (62%)	79 + 8 (-)	Positive
Gopalraj, 2004	USA (ROS)	CO	3 (detail)	86 (57%)	C	-	88 + 6.1 (-)	69 (48%)	82 + 6.3 (-)	Positive
Lamsa, 2007	Finland	CL	6 (detail)	405 (69%)	C	71.6 + 7.3 (-)	-	463 (60%)	69.9 + 5.1 (-)	Positive
Lendon, 1997	Unknown	CL	1 (detail)	115 (50%)	C	69.9 + 10.4 (-)	76.9 + 10.4 (-)	70 (57%)	79.8 + 10.7 (-)	Negative
Li, 2008	Canada	CL	2 (detail)	753 (58%)	C	71.9 + 8.5 (-)	77.8 + 8.6 (-)	736 (64%)	73.4 + 7.9 (-)	Negative
Papassotiropoulos, 2005	I (Greece)	CL	1 (detail)	134 (-)	C	-	-	45 (-)	-	Negative
Papassotiropoulos, 2005	II (Germany, Switzerland)	CL	1 (detail)	150 (-)	C	-	-	216 (-)	-	Negative
Randall, 2009	Overlaps with Cheng, 2005	CL	2 (detail)	181 (71%)	C	-	-	119 (52%)	-	n.a.
Reiman, 2007	USA, Netherlands	CL	1 (detail)	861 (-)	M	-	74.9 + 6.6 (-)	550 (-)	77.4 + 7.3 (-)	Negative
Retz, 2001	Germany	CL	2 (detail)	63 (68%)	C	66.6 + 11.9 (-)	73.7 + 9.3 (-)	162 (62%)	70.6 + 8.2 (-)	Trend
Rodriguez, 2005	Overlaps with Rodriguez, 2006	CL	1 (detail)	274 (68%)	C	71.6 + 8.6 (48-94)	75.4 + 8.7 (50-97)	283 (71%)	80.5 + 7.9 (63-100)	n.a.
Rodriguez, 2006	Spain	CL	3 (detail)	322 (68%)	C	72 + 8.5 (48-94)	75.6 + 8.6 (50-97)	314 (71%)	80.4 + 7.7 (63-100)	Negative
Scacchi, 2001	Italy	CL	1 (detail)	85 (76%)	C	-	86.1 + 3.8 (81-95)	156 (58%)	83.9 + 3.1 (80-99)	Negative
Zou, 2008	USA (MCJ)	CL	1 (detail)	577 (63%)	C	-	78.4 + 6.7 (-)	566 (60%)	78 + 7.6 (-)	Negative
Zou, 2008	USA (RS-AUT)	CL	1 (detail)	1090 (61%)	M	-	81.6 + 6.7 (-)	1126 (54%)	78.5 + 6 (-)	Positive
Zou, 2008	USA (ROS)	CL	1 (detail)	84 (56%)	N	-	87.7 + 6.4 (-)	69 (48%)	81.4 + 6.5 (-)	Trend

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

2. Family-Based Studies (by ethnic group)
				Affecteds				Unaffecteds
Study	Population	# Polys	# Families	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result	Comment
Other/Mixed
Bertram, 2005	USA (NIMH)	3 (detail)	202	440 (-)	M	71.2 + 7.4 (-)	-	348 (-)	-	Negative

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine AD diagnosis -> "C" (clinical AD diagnosis), "N" (neuropathological AD diagnosis), "M" (mixed, i.e. AD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between); results obtained in duplicate or largely overlapping samples are listed as "n.a.".
(-) :  Either no data provided or in case of overlap, data included in original study.

AlzGene Recent Updates

AlzGene Top Results